Omnicell (NASDAQ:OMCL) Issues Quarterly Earnings Results

Omnicell (NASDAQ:OMCL) posted its quarterly earnings results on Thursday. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12), Zacks reports. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. Omnicell updated its Q1 2025 guidance to 0.150-0.250 EPS and its FY 2025 guidance to 1.650-1.850 EPS.

Omnicell Stock Down 5.3 %

Shares of NASDAQ OMCL traded down $2.34 during midday trading on Thursday, hitting $42.05. The stock had a trading volume of 361,530 shares, compared to its average volume of 327,135. The company has a market cap of $1.95 billion, a P/E ratio of -108.19, a PEG ratio of 30.78 and a beta of 0.78. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The business’s 50 day moving average is $44.52 and its 200-day moving average is $43.23.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Craig Hallum lifted their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Bank of America cut their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. Benchmark restated a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research note on Tuesday. Finally, Wells Fargo & Company lowered their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Omnicell has a consensus rating of “Hold” and an average target price of $52.33.

Insider Buying and Selling at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now owns 58,427 shares in the company, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.64% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.